Abstract
A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).
Original language | English (US) |
---|---|
Pages (from-to) | 4063-4072 |
Number of pages | 10 |
Journal | Abdominal Radiology |
Volume | 45 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2020 |
Keywords
- Axumin
- Bombesin
- Choline
- Fluciclovine
- GRPR
- PSMA
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging
- Gastroenterology
- Urology